As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase ...

WeDriveU Customers Named Best Workplaces and Best Universities for Commuters in 2025 WeDriveU logo Annual award program honors emplo ...

The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...

The changes at Spark follow Roche's decision last year to halt development of a gene therapy for hemophilia A that was the ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...

The United States Department (DOJ) of Justice logo. seal (DOJ via Bay City News ... Mangi was reportedly assigned to a Genentech-sponsored study being conducted at Stanford for breast cancer ...